Ionis (IONS) Stock: Why It Fell 27% on a Tryngolza Guidance Cut

Quick answer

Ionis fell 26.9% to $28.83 at 9:44am ET on Nov 9, 2026, from a $39.42 close, after it cut its 2026 sales guidance for TRYNGOLZA, its drug for severe hypertriglyceridemia (sHTG), to about $50 million from $100 million to $110 million. The release came out at 7am ET with third-quarter results. Management said the launch "ramps more gradually than expected reflecting early dynamics of establishing a new treatment paradigm." TRYNGOLZA sold $9 million in the quarter. The stock set a 52-week low of $28.67 and the drop took about $1.8 billion off its market value, while the broad market was higher and biotech funds were roughly flat.

Our view: Bearish through December 31, 2026, the end of the quarter in which Europe is due to decide on TRYNGOLZA and the new guidance gets its first test. The case for the stock: the rest of the report was sound, with revenue up 55%, DAWNZERA sales of $37 million on track for its $110 million to $120 million guide, total revenue and cash guidance unchanged, $1.9 billion of cash (about 40% of the market value after the drop), RSI at 18 and a stock 67% below its 52-week high. The case against carries more weight into year end. The new number implies about $9 million of TRYNGOLZA sales in the fourth quarter, flat with the third, where the old guide needed roughly $59 million to $69 million. Management said in August that it was "absolutely meeting the expectations of the launch" and reaffirmed $100 million to $110 million, so the cut costs credibility as well as revenue. The release gives no specific cause beyond a "gradual" ramp, and the average analyst target of $84.92 was set before the news and has not yet reset. We would move off Bearish if the European Commission approves the sHTG label on time, if Ionis names specific fixes such as payer coverage or prescriber counts that show up in new-patient numbers before year end, or if analysts cut their 2027 TRYNGOLZA estimates by less than the price implies. This is a view on direction over that window, not a recommendation to trade the stock.

Ionis daily closing price from Sep 28 to Nov 9, 2026, with the Oct 28 close, the Nov 6 close before results and the Nov 9 low marked

Key takeaways

Ionis fell 26.9% to $28.83 at 9:44am ET on Nov 9, 2026, from a $39.42 close, and set a 52-week low of $28.67, after cutting 2026 TRYNGOLZA sales guidance to about $50 million from $100 million to $110 million.
Third-quarter TRYNGOLZA sales were $9 million, up from $5 million in the second quarter but far below the roughly $59 million to $69 million a quarter the old guidance needed in the fourth quarter.
The rest of the report was steady: revenue rose 55% to $243 million, DAWNZERA sold $37 million, and 2026 total revenue, operating loss and year-end cash guidance were unchanged.
Ionis ended September with $1.9 billion of cash and short-term investments, about 40% of its market value after the drop.
Our view is Bearish through December 31, 2026: the new guidance implies no fourth-quarter ramp, management reaffirmed the old number three months ago, and analyst targets have not yet caught up with the price.

Table of contents

Nov 9, 2026: a steady slide, then a break lower on the release
The numbers: a ramp that needed a fourth quarter that is not coming
The bull case: a drug company with cash and other launches
The risks
What comes next

Nov 9, 2026: a steady slide, then a break lower on the release

The stock was already weak into the report. It closed at $39.42 on Nov 6, down from $44.90 on Oct 28. Premarket trading began near $40 and it was at $36.02 at 7am, when Ionis filed its 8-K and press release. It traded at $32.50 by 8am, filed its 10-Q at 8:33am, and was at $32.01 at 9am, when management started its call. The premarket low was $30.00. It opened at $31.96, the high of the session so far was $32.58, and it dropped to $29.47 by 9:35am and a low of $28.67 at 9:44am. About 2.1 million shares had traded by 9:44am.

What happened:

The guide. TRYNGOLZA net product sales guidance for 2026 fell to about $50 million from $100 million to $110 million. Nine-month sales were $41 million, so $50 million leaves about $9 million for the fourth quarter. The old range needed $59 million to $69 million.
The quarter. TRYNGOLZA sold $9 million, up from $5 million in the second quarter, and down from $32 million in the third quarter of 2025. In August, CFO Elizabeth Hougen blamed the second-quarter dip on the April 1 list price cut and said she expected TRYNGOLZA "to return to revenue growth in the second half of this year as the sHTG launch gains momentum."
The company's words. CEO Brett Monia said "initial sales progress has been more gradual than anticipated," and Hougen said Ionis "remain[s] confident in TRYNGOLZA's potential to deliver sustained, long-term revenue growth and multi-billion-dollar peak sales."
What held. Total revenue was $243 million against $157 million a year earlier. DAWNZERA sold $37 million, and 2026 guidance for total revenue ($875 million to $900 million), non-GAAP operating loss ($425 million to $475 million) and year-end cash (more than $1.6 billion) was unchanged.

Ionis was the outlier. From the Nov 6 close, at about 9:44am:

Stock or fund	Nov 6 close	Nov 9, ~9:44am	Change
Arrowhead (ARWR)	$58.16	$50.22	-13.7%
Alnylam (ALNY)	$155.94	$153.16	-1.8%
SPDR S&P Biotech (XBI)	$152.21	$151.19	-0.7%
BridgeBio (BBIO)	$74.29	$73.84	-0.6%
iShares Biotechnology (IBB)	$213.63	$213.44	-0.1%
Ionis (IONS)	$39.42	$28.83	-26.9%

Arrowhead, which also has a triglyceride-lowering drug, fell with Ionis. It had no filing today, its last being an 8-K on Nov 5, so the fall looks like a read-across from Ionis's slow sHTG start. After the drop, RSI(14) stood at 18, the shares sat 37% below their 50-day average and 56% below their 200-day average, 67% below their 52-week high of $86.74, and volume had already reached 0.8 times its 20-day average for a full day.

The numbers: a ramp that needed a fourth quarter that is not coming

Bar chart of TRYNGOLZA net sales: $27 million in Q1 2026, $5 million in Q2, $9 million in Q3, about $64 million implied for Q4 by the old guidance midpoint and about $9 million implied by the new guidance

The first quarter of $27 million was the familiar familial chylomicronemia syndrome (FCS) business. The second quarter, at $5 million, followed the April list price cut. The third, at $9 million, was the first quarter of sHTG selling, and it grew only a little. The old guidance would have needed a sevenfold jump in the fourth quarter. The new one assumes none. Our explainers on why guidance changes move stocks and how estimate revisions follow cover why a guide cut can keep weighing on a stock while forecasts reset.

The bull case: a drug company with cash and other launches

Cash. Ionis had $1.9 billion at the end of September, down from $2.7 billion at the end of 2025 mainly because it repaid its 0% convertible notes on April 1. Our guide to net cash per share shows how much of the price that covers.
Other launches. DAWNZERA sold $37 million in the quarter, ZANVASTRO for Alexander disease launched, and HIBSAGO for chronic hepatitis B, a partnered drug, is approved in the US, Japan and Canada.
Partner royalties and data. SPINRAZA royalties were $69 million. The partnered drug sefaxersen cut proteinuria by 43.1% in a Phase 3 IgA nephropathy study, and the ulefnersen Phase 3 in FUS-ALS met its primary endpoint.
Europe. The EMA's human medicines committee gave a positive opinion for TRYNGOLZA in sHTG, and a final decision is expected in the fourth quarter.

The risks

No sign of a ramp. The new guide implies a flat fourth quarter, and the release does not say what Ionis will change, only that it has "identified clear opportunities to improve performance."
The revenue guide leans on partners. Research and development revenue from partners was $107 million of the $243 million quarter, and the reaffirmed $875 million to $900 million guide implies $118 million to $143 million in the fourth quarter after $757 million in nine months.
Targets that have not reset. The average analyst target of $84.92, with a range of $56 to $115, was set before the news, and 12.7% of the float is sold short. Our guides to analyst rating changes and short interest explain how those can move.
Pipeline setbacks. The Phase 3 study of eplontersen in cardiomyopathy missed its primary composite endpoint in the overall population. We covered the partner's own reset in why Alnylam stock fell.

What comes next

The European decision on TRYNGOLZA in sHTG is expected in the fourth quarter. Investor conferences before year end are where management could name its fixes, and our guide to analyzing an earnings call transcript shows what to listen for. Fourth-quarter results will test the roughly $9 million implied for TRYNGOLZA, and obudanersen Phase 3 data in Angelman syndrome follow in the second half of 2027. For how a pipeline is valued in the meantime, see our guide to valuing a biotech pipeline, and for more of the day's swings see today's biggest stock moves. Dombey's published work on events like this is in the research archive.

Frequently asked questions

Why did Ionis stock drop today?

Ionis fell 26.9% to $28.83 at 9:44am ET on Nov 9 after it cut its 2026 TRYNGOLZA net sales guidance to about $50 million from $100 million to $110 million. The company said the launch in severe hypertriglyceridemia, or sHTG, is ramping more gradually than it expected. Third-quarter TRYNGOLZA sales were $9 million.

Did Ionis miss earnings?

Total results were not the problem. Third-quarter revenue rose 55% to $243 million from $157 million, the loss from operations narrowed to $130 million from $160 million, and Ionis reaffirmed 2026 total revenue guidance of $875 million to $900 million. The drop came from the TRYNGOLZA guidance cut.

What is TRYNGOLZA?

TRYNGOLZA (olezarsen) is Ionis's own drug, approved to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, and to reduce triglycerides in adults with familial chylomicronemia syndrome. It is the company's first launch in a large indication, and management has said it can reach multi-billion-dollar peak sales.

How much cash does Ionis have?

Ionis ended September with $1.9 billion in cash, cash equivalents and short-term investments, down from $2.7 billion at the end of 2025, mainly because it repaid its 0% convertible notes on April 1 and funded operations. It guides to more than $1.6 billion at year end.

Did Arrowhead stock fall too?

Yes. Arrowhead, which is also developing a triglyceride-lowering drug, fell 13.7% at about 9:44am ET. It had no filing or announcement of its own on Nov 9. Alnylam fell 1.8%, BridgeBio 0.6% and the SPDR S&P Biotech fund 0.7%.

What are the next catalysts for Ionis?

A final European decision on TRYNGOLZA for sHTG is expected in the fourth quarter of 2026, after a positive opinion from the EMA's human medicines committee. Fourth-quarter results will show whether TRYNGOLZA sales reached the roughly $9 million the new guidance implies. Phase 3 data for obudanersen in Angelman syndrome are expected in the second half of 2027.

Sources

Article details

By James Whitfield, Head of Equity Research, Dombey Capital

Published November 9, 2026 · 6 min read · Event-Driven Investing